{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:55Z","timestamp":1790821555828,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["202240383"],"award-info":[{"award-number":["202240383"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04727-6","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:06:08Z","timestamp":1771409168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Siponimod for relapsing-remitting multiple sclerosis: a single-center, real-world cohort study in China"],"prefix":"10.1186","volume":"26","author":[{"given":"Hongmei","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanzhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzi","family":"ZhangBao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"4727_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","volume":"167 5","author":"P Gergely","year":"2012","unstructured":"Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167 5:1035\u201347. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.02061.x.","journal-title":"Br J Pharmacol"},{"key":"4727_CR2","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/j.1476-5381.2009.00451.x","volume":"158 5","author":"V Brinkmann","year":"2009","unstructured":"Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158 5:1173\u201382. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00451.x.","journal-title":"Br J Pharmacol"},{"key":"4727_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12974-016-0686-4","volume":"13 1","author":"A Gentile","year":"2016","unstructured":"Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflamm. 2016;13 1:207. https:\/\/doi.org\/10.1186\/s12974-016-0686-4.","journal-title":"J Neuroinflamm"},{"key":"4727_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1742-2094-8-76","volume":"8","author":"SJ Jackson","year":"2011","unstructured":"Jackson SJ, Giovannoni G, Baker D. Fingolimod modulates microglial activation to augment markers of remyelination. J Neuroinflamm. 2011;8:76. https:\/\/doi.org\/10.1186\/1742-2094-8-76.","journal-title":"J Neuroinflamm"},{"key":"4727_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/s0140-6736(18)30475-6","volume":"391 10127","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet (London England). 2018;391 10127:1263\u201373. https:\/\/doi.org\/10.1016\/s0140-6736(18)30475-6.","journal-title":"Lancet (London England)"},{"key":"4727_CR6","doi-asserted-by":"publisher","first-page":"175628642412391","DOI":"10.1177\/17562864241239117","volume":"17","author":"J Guo","year":"2024","unstructured":"Guo J, Wu J, Wang L, Liu H, Wu X, Yang H, et al. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China. Ther Adv Neurol Disord. 2024;17:17562864241239117. https:\/\/doi.org\/10.1177\/17562864241239117.","journal-title":"Ther Adv Neurol Disord"},{"key":"4727_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","volume":"17 2","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17 2:162\u201373. https:\/\/doi.org\/10.1016\/s1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"key":"4727_CR8","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33 11","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33 11:1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"key":"4727_CR9","doi-asserted-by":"publisher","first-page":"1343531","DOI":"10.3389\/fimmu.2024.1343531","volume":"15","author":"H Tan","year":"2024","unstructured":"Tan H, Li X, Li Y, He F, ZhangBao J, Zhou L, et al. Real-world experience of Teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions May play a role. Front Immunol. 2024;15:1343531. https:\/\/doi.org\/10.3389\/fimmu.2024.1343531.","journal-title":"Front Immunol"},{"issue":"Pt 11","key":"4727_CR10","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138(Pt 11):3287\u201398. https:\/\/doi.org\/10.1093\/brain\/awv258.","journal-title":"Brain"},{"issue":"5","key":"4727_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","volume":"23","author":"RH Benedict","year":"2017","unstructured":"Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721\u201333. https:\/\/doi.org\/10.1177\/1352458517690821.","journal-title":"Mult Scler"},{"key":"4727_CR12","doi-asserted-by":"publisher","unstructured":"Gilmartin CG, Hoyle N, Garjani A, Dixon T, Jos H, Paling D et al. Real-world data on siponimod-related lymphopenia among people with secondary progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2024;30 4\u20135:600\u20134; https:\/\/doi.org\/10.1177\/13524585231225711","DOI":"10.1177\/13524585231225711"},{"key":"4727_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/s1474-4422(13)70102-9","volume":"12 8","author":"K Selmaj","year":"2013","unstructured":"Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12 8:756\u201367. https:\/\/doi.org\/10.1016\/s1474-4422(13)70102-9.","journal-title":"Lancet Neurol"},{"key":"4727_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","volume":"73 9","author":"L Kappos","year":"2016","unstructured":"Kappos L, Li DK, St\u00fcve O, Hartung HP, Freedman MS, Hemmer B, et al. Safety and efficacy of Siponimod (BAF312) in patients with Relapsing-Remitting multiple sclerosis: Dose-Blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016;73 9:1089\u201398. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1451.","journal-title":"JAMA Neurol"},{"key":"4727_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362 5","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral Fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362 5:387\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa0909494.","journal-title":"N Engl J Med"},{"key":"4727_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/s1474-4422(19)30239-x","volume":"18 11","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18 11:1009\u201320. https:\/\/doi.org\/10.1016\/s1474-4422(19)30239-x.","journal-title":"Lancet Neurol"},{"key":"4727_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/s1474-4422(19)30238-8","volume":"18 11","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019;18 11:1021\u201333. https:\/\/doi.org\/10.1016\/s1474-4422(19)30238-8.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4727_CR18","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/wnl.0000000000011275","volume":"96","author":"RHB Benedict","year":"2021","unstructured":"Benedict RHB, Tomic D, Cree BA, Fox R, Giovannoni G, Bar-Or A, et al. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses. Neurology. 2021;96(3):e376\u201386. https:\/\/doi.org\/10.1212\/wnl.0000000000011275.","journal-title":"Neurology"},{"issue":"6","key":"4727_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1352458517707345","volume":"24","author":"RH Benedict","year":"2018","unstructured":"Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: results from the DECIDE study. Mult Scler. 2018;24(6):795\u2013804. https:\/\/doi.org\/10.1177\/1352458517707345.","journal-title":"Mult Scler"},{"key":"4727_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/s1474-4422(20)30277-5","volume":"19 10","author":"RHB Benedict","year":"2020","unstructured":"Benedict RHB, Amato MP, DeLuca J, Geurts JJG. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19 10:860\u201371. https:\/\/doi.org\/10.1016\/s1474-4422(20)30277-5.","journal-title":"Lancet Neurol"},{"key":"4727_CR21","doi-asserted-by":"publisher","first-page":"e2373","DOI":"10.1212\/wnl.0000000000009522","volume":"94 22","author":"NC Landmeyer","year":"2020","unstructured":"Landmeyer NC, B\u00fcrkner PC, Wiendl H, Ruck T, Hartung HP, Holling H, et al. Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis. Neurology. 2020;94 22:e2373\u201383. https:\/\/doi.org\/10.1212\/wnl.0000000000009522.","journal-title":"Neurology"},{"key":"4727_CR22","doi-asserted-by":"publisher","unstructured":"Sancho-L\u00f3pez A, Ruiz-Antor\u00e1n B, Hernang\u00f3mez TI, Ram\u00edrez-Garc\u00eda A, G\u00f3mez-Est\u00e9vez I, Sanabria-Cabrera J, et al. The need for the closer monitoring of novel drugs in MS: A Siponimod retrospective cohort study (Realhes study). J Clin Med. 2023;12(20). https:\/\/doi.org\/10.3390\/jcm12206471.","DOI":"10.3390\/jcm12206471"},{"key":"4727_CR23","doi-asserted-by":"publisher","unstructured":"Regner-Nelke L, Pawlitzki M, Willison A, Rolfes L, Oezalp SH, Nelke C, et al. Real-world evidence on Siponimod treatment in patients with secondary progressive multiple sclerosis. Neurol Res Pract. 2022;4(1:55). https:\/\/doi.org\/10.1186\/s42466-022-00219-3.","DOI":"10.1186\/s42466-022-00219-3"},{"key":"4727_CR24","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1007\/s00415-022-11118-7","volume":"269 9","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Yin H, Zhang D, Xu Y, Peng B, Cui L. Real-world outcomes of Teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study. J Neurol. 2022;269 9:4808\u201316. https:\/\/doi.org\/10.1007\/s00415-022-11118-7.","journal-title":"J Neurol"},{"key":"4727_CR25","doi-asserted-by":"publisher","first-page":"175628642311811","DOI":"10.1177\/17562864231181170","volume":"16","author":"B Bu","year":"2023","unstructured":"Bu B, Quan C, Li W, Zeng Q, Shi Z, Chen B, et al. The effectiveness of Teriflunomide in patients with multiple sclerosis in china: a real-world comparison to no DMT treatment in the first year after diagnosis. Ther Adv Neurol Disord. 2023;16:17562864231181170. https:\/\/doi.org\/10.1177\/17562864231181170.","journal-title":"Ther Adv Neurol Disord"},{"key":"4727_CR26","doi-asserted-by":"publisher","first-page":"103446","DOI":"10.1016\/j.msard.2021.103446","volume":"58","author":"R Zhou","year":"2022","unstructured":"Zhou R, Li H, Yang H, Jiang F, Cai H, Li J, et al. Serological markers exploration and real-world effectiveness and safety of Teriflunomide in South Chinese patients with multiple sclerosis. Multiple Scler Relat Disorders. 2022;58:103446. https:\/\/doi.org\/10.1016\/j.msard.2021.103446.","journal-title":"Multiple Scler Relat Disorders"},{"key":"4727_CR27","doi-asserted-by":"publisher","first-page":"175628641983507","DOI":"10.1177\/1756286419835077","volume":"12","author":"BA Kallmann","year":"2019","unstructured":"Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A. Real-life outcomes of Teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Ther Adv Neurol Disord. 2019;12:1756286419835077. https:\/\/doi.org\/10.1177\/1756286419835077.","journal-title":"Ther Adv Neurol Disord"},{"key":"4727_CR28","doi-asserted-by":"publisher","first-page":"727586","DOI":"10.3389\/fneur.2021.727586","volume":"12","author":"L Landete","year":"2021","unstructured":"Landete L, P\u00e9rez-Miralles F, Garc\u00eda S, Belenguer A, Gasc\u00f3n F, Dom\u00ednguez JA, et al. Treatment of multiple sclerosis with Teriflunomide. Multicenter study of real clinical practice in the Valencian Community-Spain. Front Neurol. 2021;12:727586. https:\/\/doi.org\/10.3389\/fneur.2021.727586.","journal-title":"Front Neurol"},{"key":"4727_CR29","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1007\/s00415-021-10455-3","volume":"268 8","author":"S Bucello","year":"2021","unstructured":"Bucello S, Annovazzi P, Ragonese P, Altieri M, Barcella V, Bergamaschi R, et al. Real world experience with Teriflunomide in multiple sclerosis: the TER-Italy study. J Neurol. 2021;268 8:2922\u201332. https:\/\/doi.org\/10.1007\/s00415-021-10455-3.","journal-title":"J Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04727-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04727-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04727-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:32:08Z","timestamp":1774517528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04727-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4727"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04727-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Medical Ethics Committees of Huashan Hospital. Written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"189"}}